Home › Mylan: Outperformed S&P 500 Since June, And Shows No Signs Of Slowing
 

Keywords :   


Mylan: Outperformed S&P 500 Since June, And Shows No Signs Of Slowing

2015-01-22 16:03:15| Biotech - Topix.net

Mylan has shown alpha returns over the past year, beating the S&P 500 by approximately 4% in the past four months. The outlook for the drug device combination products industry is expected to grow at a CAGR rate of 7.9% through to 2019.

Tags: of june shows signs

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
21.09Atlantic Tropical Weather Outlook
21.09Eastern North Pacific Tropical Weather Outlook
20.09Labelexpo Americas highlights, Maxcess announces acquisition and more
20.09September Cattle on Feed as expected
20.09USDA announces major investment in meat and poultry processing
20.09Atlantic Tropical Weather Outlook
20.09Eastern North Pacific Tropical Weather Outlook
20.09This weeks lesson: Weaning matters in the cattle market
More »